Clinical Trials Logo

Clinical Trial Summary

Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. The relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. The investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine.


Clinical Trial Description

Although transurethral resection is the main treatment option for stage Ta and T1 disease, relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ carcinoma and tumor grade are risk factors for recurrence. The relationship between post voiding residual urine volume and bladder tumor recurrence and progression has not been clearly established. Participants who underwent transurethral resection for bladder tumor will be included in the study. The investigators aimed to examine the effect of high post voiding residual urine volume on recurrence and progression based on the hypothesis that tumor cells circulating in the bladder may increase with excess residual urine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04617743
Study type Observational [Patient Registry]
Source Istanbul Medeniyet University
Contact Mehmet Caglar Cakici, M.D.
Phone +90 5376102438
Email mcaglarcakici@hotmail.com
Status Recruiting
Phase
Start date November 26, 2020
Completion date November 1, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05335512 - Intravesical BCG: is the Urinary Bladder Ready to Receive it
Completed NCT04647981 - Diagnostic Performance Evaluation Study of the Xpert® Bladder Cancer Monitor Test.
Not yet recruiting NCT05037279 - Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) Phase 3
Recruiting NCT05768347 - Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC Phase 1